BACKGROUND: Cystatin C is a low molecular weight cysteine proteinase inhibitor whose plasma or serum concentrations have been shown to be better correlated with glomerular filtration rate than serum creatinine concentrations. Routine assays for cystatin C are based on use of polyclonal antibodies and immunoturbidimetric and nephelometric designs. This study aimed to develop a double-monoclonal immunoassay for cystatin C.
Cystatin C is a 13.4-kDa cysteine protease inhibitor used as a clinical marker of kidney function. Cystatin C has several advantages compared with creatinine, the most commonly used renal marker (1) (2) (3) . The plasma concentration of cystatin C is more sensitive to small changes in glomerular filtration rate than that of creatinine (4 ) . Unlike cystatin C, creatinine concentration in the circulation reflects changes in factors such as diet and body mass composition (5, 6 ) . Additionally, serum concentrations of creatinine in children increase with age, whereas serum concentrations of creatinine in elderly people tend to decrease. By contrast, cystatin C remains nearly stable after 1 year of age (7 ) . Cystatin C is thus a more reliable marker for estimating kidney function in both children and elderly people.
Quantification of cystatin C is performed by immunoassays. Routine automated laboratory assays include particle-enhanced homogeneous methods using light scattering for detection. Commercial particleenhanced turbidimetric and nephelometric immunoassays (PETIA and PENIA) 5 are sold as reagent kits that enable the measurement to be performed with different analyzers. Despite this flexibility in adoption, the current methods are not standardized. Moreover, the fact that polyclonal antibodies against cystatin C are used can cause variation from batch to batch due to the challenge of producing identical immunological responses in separate immunizations. Particulate matter and lipemia are also recognized to variably interfere with assays based on turbidimetric detection principles (8 ) .
The aim of this study was to develop a doublemonoclonal, noncompetitive assay for cystatin C that can be performed using a commercially available allin-one dry-reagent instrument (9 ) and that would enable high reproducibility and robustness. As part of this process, we constructed an epitope map using 7 monoclonal antibodies.
The use of monoclonal antibodies in an immunoassay for cystatin C offers several advantages over the use of polyclonal antibodies, including the possibility to optimally select between different antibodies (affinities, kinetics) and a constant supply of selected antibodies that are uniform products between batches. In addition, a 2-site assay provides several benefits. The use of excess antibody makes the assay sensitive, which enables dilution of sample material. Although cystatin C concentrations in circulation do not require the high analytical sensitivity offered by a noncompetitive assay design, a dilution-based assay may reduce some nonspecific matrix interferences, particularly heterophilic interference, which is of concern in turbidimetric assays.
Materials and Methods

CALIBRATORS AND CLINICAL SAMPLES
We used recombinant cystatin C, produced in an Escherichia coli expression system, in the calibrator (10 ) . Leftover, deidentified plasma samples (n ϭ 132) used for the method-comparison assays and recovery studies were collected in lithium-heparin at the University Hospital of Lund. The samples were frozen the same day they were analyzed on the Roche Cobas 6000 and were shipped to the University of Turku on dry ice and stored frozen at Ϫ70°C until analyzed with the developed assays. We obtained plasma and serum samples used in assay evaluation and interference studies from volunteers of the staff at the Department of Biotechnology, University of Turku, Turku, Finland. These samples were either analyzed fresh or stored frozen at Ϫ70°C.
ANTIBODIES
We acquired 6 monoclonal cystatin C mouse antibodies, Cyst10, Cyst13, Cyst19, Cyst23, Cyst24, and Cyst28, from HyTest. The antibodies were raised against purified, endogenous human cystatin C and were of IgG1 subclass, except for Cyst10, which represented IgG3 subclass. One monoclonal cystatin C-specific mouse antibody, HCC3, was prepared as described by Olafsson et al. (11 ) .
OTHER REAGENTS
Nona-dentate Eu 3ϩ fluorescent chelate, {2,2Ј,2Љ,2ЈЉ-{[2-(4-isothiocyanatophenyl)ethylimino]bis(methylene)bis{4-{[4-(R-galactopyranoxy)phenyl]ethynyl}pyri-dine-6,2-diyl}bis(methylenenitrilo)}tetrakis(acetato)} europium 3ϩ , was synthesized at the Department of Biotechnology as described (12 ) . Biotin isothiocyanate (BITC), Aio! buffer, and streptavidin-coated single microtitration wells and strips were from Innotrac Diagnostics, NAP-5™ and NAP-10™ columns from GE Healthcare, BSA from Sigma Aldrich, and all other chemicals used were of analytical grade.
INSTRUMENTATION
Victor
2 1420 multilabel counter for time-resolved fluorescence measurement and the Delfia platewash were from Perkin-Elmer Life and Analytical Sciences, Wallac, the automated Aio! all-in-one immunoanalyzer from Innotrac Diagnostics, and the fast-performance liquid chromatography (FPLC) system with a Superdex™ 200 HR 10/30 column was from GE Healthcare, formerly Pharmacia Biotech.
CONJUGATION OF BIOTIN AND EU-CHELATE TO ANTIBODIES
The biotinylation of capture antibodies and purification of the reaction products were conducted as described (13 ) . We used 0.5 g/L antibody solution in 50 mmol/L sodium carbonate buffer, pH 9.6, and a 25-fold molar excess of BITC in the labeling reaction. We carried out reactions for 3 h at room temperature and removed excess free reagents with disposable NAP-5 and NAP-10 gel filtration columns equilibrated and eluted with 50 mmol/L Tris buffer, pH 7.75, containing 150 mmol/L NaCl and 0.5 g/L NaN 3 . We stored biotinylated antibodies at 4°C after addition of BSA to the final concentration of 1 g/L.
We labeled the detection antibodies with 25-to 35-fold molar ratios of nona-dentate Eu 3ϩ chelate. Reactions were mixed briefly and allowed to incubate at room temperature for 16 h in 50 mmol/L sodium carbonate buffer, pH 9.6. We separated the labeled antibodies from free chelate by gel filtration chromatography using a Superdex 200 HR 10/30 column according to a method described previously (12 ) . The fractions containing the labeled antibody were determined and pooled, and europium concentrations were measured against a europium calibrator using Delfia method (PerkinElmer Life and Analytical Sciences, Wallac). We determined IgG concentrations with the Bio-Rad Protein Assay (Bio-Rad Laboratories). We added BSA to pooled antibody solutions to the final concentration of 1 g/L and stored labeled antibodies at 4°C. The obtained labeling of antibodies varied from 2.4 to 13 Eu 3ϩ molecules per IgG molecule.
ASSAY DESIGN FOR EPITOPE MAPPING AND ANTIBODY PAIR
SELECTION
We used a 1-step reagent excess assay design to investigate functional antibody pairs. We first applied 200 ng biotinylated capture antibody in assay buffer (50 mmol/L Tris, pH 7.75, 154 mmol/L NaCl, 0.5 g/L NaN 3 , 0.1 g/L Tween 40, 0.5 g/L bovine ␥-globulin, 20 mol/L diethylenetriaminepentaacetate, and 5 g/L BSA) to streptavidin-coated microtitration wells. After 60 min at ambient temperature with shaking, the wells were washed twice with wash solution (5 mmol/L Tris, pH 7.75, containing 154 mmol/L NaCl, 5 g/L Tween 20, and 1 g/L Germall II), and 200 ng of detection antibody and standard or 100-fold diluted sample were added. We prepared detection antibody solutions in assay buffer enhanced with 2 blockers: 0.1 g/L native and 0.05 g/L denatured mouse IgG (Biodesign International). All standard and sample dilutions were prepared in sample dilution buffer (50 mmol/L Tris buffer, pH 7.75, containing 150 mmol/L NaCl, 0.5 g/L NaN 3 , and 60 g/L BSA). Reaction wells were incubated at 36°C with continuous shaking (900 rpm) and, after incubation, washed 6 times, dried, cooled to room temperature, and measured with Victor 2 counter. We used functional antibody combinations (26 of 42) to further evaluate binding kinetics of the 1-step assay with both recombinant cystatin C and endogenous cystatin C in plasma. We studied the speed of the 2-site complex formation by comparing net signals after 10 and 60 min of incubation. We further screened 12 of these 2-site combinations for linearity of the dose-response curve and 8 combinations for speed and consistency of signal increase within 10 -120 min of incubation. Based on these studies, we chose 3 antibody pairs for detailed investigation.
PREPARATION OF ALL-IN-ONE DRY REAGENT WELLS
Three antibody pairs were studied more extensively, and assays using them were transferred to Aio! all-inone immunoanalyzer format. We prepared dryreagent wells as described by Lövgren et al. (14 ) with the following modifications. We immobilized 200 ng biotinylated capture antibody in assay buffer onto streptavidin-coated single microtiter wells. We added strongly buffered insulating solution containing (per liter) 37.5 mmol Tris, 120 mmol NaCl, 0.375 g NaN 3 , 0.6 g bovine ␥-globulin, 25 g BSA, 50 g D-trehalose, 0.1 g native mouse IgG, 0.05 g denatured mouse IgG, and 2 g casein (pH 7.75) to cover and protect the capture antibody, and the wells were dried at 35°C for 20 h. Europium-labeled detection antibody (100 ng/ well) in a 1-L volume was dispensed on top of the insulation layer and immediately dried for 3 min under a stream of warm air (60°C). The wells were stored at 4°C, protected from humidity, for a maximum of 4 weeks before being used in an assay.
ALL-IN-ONE CYSTATIN C IMMUNOASSAY
We diluted samples 1:100 with sample dilution buffer before analysis with the Aio! immunoanalyzer. The automated assay procedure was as follows: 10 L of diluted sample and 20 L of Aio! buffer, which is a combined assay and wash buffer of the Aio! immunoanalyzer (15 ) , were applied into the dry-reagent well and incubated for 10 min at 36°C with shaking. The unbound detection antibody was removed in the subsequent washing step in which the well was washed 6 times in total. Wells were then aspirated and dried under a stream of hot air (95°C). We measured fluorescence using the default settings of the Aio! immunoanalyzer (12 ) .
COMPARISON METHOD
We measured plasma cystatin C with PETIA (16 ) using the Roche Cobas 6000 analysis system. We obtained the reagents from Roche, including the calibrator based on a delipidated stabilized serum pool to which recombinant cystatin C had been added (cat. no. 04975901 190). The total analytical imprecision was 2.1% (using a control sample at a concentration of 1.0 mg/L) and 1.7% (at a level of 4.0 mg/L). Because of a skewed distribution of cystatin C values of the plasma samples, we used the Spearman rank correlation to assess the correlation between the developed assay and the PETIA assay. We calculated Deming regression parameters with GraphPad Prism 4 statistical software (GraphPad Software).
ASSAY EVALUATIONS
We performed final assay evaluations for the selected antibody combination (Cyst28-Cyst24) only. We studied the linearity of sample dilution series by diluting 3 plasma samples (0.77, 1.4, and 2.5 mg/L) and 2 serum samples (0.84 and 0.97 mg/L) 3-to 6561-fold with the sample dilution buffer and measuring the concentrations of all dilutions against a calibration curve. We used linear regression analysis to estimate linearity of the dilution series and estimated functional detection limits of the assays from the imprecision profiles of the sample dilution series (6 replicate measurements), defined as the concentration of cystatin C that could be measured with a CV of 20%.
We prepared samples for recovery studies by diluting 3 plasma samples, whose initial cystatin C concentrations were 0.84, 1.62, and 2.91 mg/L, 1:100 with sample dilution buffer and adding plasma cystatin C to these dilutions so that the increase in cystatin C concentration ranged from 17% to 240%. Two plasma samples containing a high concentration of cystatin C (5.04 and 5.51 mg/L) were diluted and used for additions. The change in original cystatin C concentration due to added volume (5% of the total sample volume) was taken into consideration when calculating the recovery percentages.
We determined within-run and total assay imprecisions according to Clinical Laboratory Standards Institute (CLSI) Guideline EP5-A. Imprecision was studied with 3 heparinized plasma samples; their mean cystatin C concentrations measured with the selected antibody pair were 0.84, 2.0, and 3.2 mg/L. The samples were assayed twice a day for 20 days in duplicate, together with clinical plasma and serum samples.
We carried out interference testing for bilirubin, hemoglobin, and triglycerides (as Intralipid, SigmaAldrich) according to CLSI Guideline EP7-A except for the use of commercial hemoglobin (Sigma-Aldrich) at 2 concentrations, 1.0 and 5.0 g/L, instead of hemolysate. Fresh plasma pool was enhanced with recombinant cystatin C to prepare the 2 samples (1.0 and 2.0 mg/L) used in this test.
Results
EPITOPE MAP AND ANTIBODY PAIR SELECTION
Of the 42 antibody pairings investigated in 2-site immunoassays, 26 pairings generated a response more than 2 times the nonspecific background signal with both recombinant and endogenous (plasma) cystatin C and therefore were considered to have the ability to form 2-site complexes with both forms of cystatin C. Based on these results, we constructed a schematic epitope map (Fig. 1) .
The results suggested that 4 different epitopes were present: (a) Cyst23, Cyst24; (b) Cyst10; (c) Cyst13, Cyst19; and (d) HCC3 (Fig. 1) . Antibodies Cyst23 and Cyst24 provided binding patterns identical to those of the other antibodies and apparently recognized highly similar epitopes. The same applied for Cyst13 and Cyst19. Cyst28 most likely detected the same epitope as Cyst13 and Cyst19, although slight differences were noticed. The previously reported HCC3 antibody represented a fourth epitope group that overlapped with epitope groups b and c.
After selection of pairs that enabled a 10-to 60-min binding ratio between 76% and 104% and consistent binding of recombinant and plasma cystatin C (difference Ͻ10%), the number of pairs with acceptable functionality decreased to 12 (see Supplemental  Table 1 , which accompanies the online version of this article at http://www.clinchem.org/content/vol56/ issue9). The number of antibody combinations further decreased to 8 after exclusion of the antibody pairs Cyst10-Cyst23, Cyst10-Cyst24, Cyst24-Cyst10, and Cyst28-Cyst10, which did not produce uniform doseresponses over 3 decades of recombinant cystatin C (0.0005-0.5 mg/L). The final selection criteria included equal binding rates of recombinant and plasma cystatin C, an increasing signal with a lowconcentration plasma sample (with 100-fold dilution: 0.007 mg/L) over time, and Ͻ10% decrease in signal per hour after the steady state of binding was reached. According to these criteria, we selected 3 capturedetection combinations, HCC3-Cyst24, Cyst24-Cyst19, and Cyst28-Cyst24.
CALIBRATION CURVES AND ASSAY KINETICS
Calibration curves obtained with the 3 antibody pairs are shown in Fig. 2 . Recombinant cystatin C was di- 
Fig. 2. Calibration curves (open symbols) and precision profiles (filled symbols) for the 3 developed immunoassays for cystatin C.
Squares, antibody pair Cyst24-Cyst19 (capture-detection); triangles, pair HCC3-Cyst24; diamonds, pair Cyst28-Cyst24. The values shown are means of 6 determinations. CVconc, concentration CV (CV that has been calculated from concentration values, not from signals).
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luted to cover concentrations from 0.0001 to 0.5 mg/L (corresponding plasma cystatin C concentrations 0.01-50 mg/L), and 6 determinations were made to calculate CVs. The analytical detection limit of the assay, calculated as the mean background signal ϩ 3 SD, was Յ0.0001 mg/L (corresponding plasma concentration Յ0.01 mg/L) for all 3 antibody-pairs. The difference in signal level between detection antibodies Cyst19 and Cyst24 was in accordance with the difference in molar fraction of the label attached to the detection antibody (6.2 vs 2.4 Eu/IgG).
We studied assay kinetics by measuring low-, medium-, and high-concentration samples of both recombinant and endogenous cystatin C using a 10 -120 min reaction time. Results are available in online Supplemental Fig. 1 . The steady state for binding was reached in 60 min, and in 10 min the obtained signal level was approximately 84%, 93%, and 96% of the steady-state signal level for the antibody pairs Cyst24-Cyst19, Cyst28-Cyst24, and HCC3-Cyst24, respectively. Despite the fastest binding, the antibody pair HCC3-Cyst24 showed the highest difference in kinetics properties of plasma samples vs recombinant cystatin C (see online Supplemental Fig. 1) . Binding was the most consistent throughout the working range with the pair Cyst28-Cyst24.
METHOD COMPARISON
We investigated applicability of the developed assays to Comparison of results between the doublemonoclonal assay using antibodies Cyst28 and Cyst24 and the control assay (PETIA) is shown in Fig. 3A (Fig. 3, B and C) . The developed assay produced values that were about 20% higher than the PETIA concentrations of the same samples. Among the 132 plasma samples, the analysis platform used, Roche Cobas 6000, automatically labeled 13 samples as "lipemic" or "hemolytic" or both. No samples were labeled "icteric." The 13 samples were visually inspected and classified as "moderately" or "heavily" lipemic and/or hemolytic. The results for these samples can be seen in Table 1 . One sample was excluded from all correlation and agreement studies: this plasma sample was marked as containing clots, which likely was the cause for the low PETIA cystatin C value (0.47 mg/L). For comparison, the creatinine value of the same sample was 803 mol/L.
Due to excellent linearity, fast binding, and good correlation with the control assay, the assay using antibodies Cyst28 and Cyst24 was selected for further evaluation.
CYST28-CYST24 ASSAY EVALUATION
We estimated linearity of the assay with 3-to 6561-fold dilutions of 3 plasma and 2 serum samples. The assay response was linear when measured and estimated cystatin C concentrations were compared (Fig. 4A) . The functional detection limit was calculated from CVs of sample dilution series (Fig. 4B) , and the undiluted cystatin C concentration that corresponds to a CV value of 20% was 0.02 mg/L for the pair Cyst28 -Cyst24.
To measure the analytical recovery values, we spiked 3 plasma sample dilutions with 2 highconcentration plasma samples. The assay recoveries varied from 94% to 110%. Within-run and total assay imprecisions were measured with the selected antibody pair, Cyst28-Cyst24, using 3 control samples. The measured mean concentrations of the control samples were 0.84, 2.0, and 3.2 mg/L. The within-run imprecisions were 4.6%, 3.8%, and 2.8%, and the total assay imprecisions 4.6%, 3.9%, and 5.5%, respectively.
Bilirubin at 257 mol/L, hemoglobin at 5 g/L, and triglycerides at 5.6 mmol/L did not interfere with the assay as tested at 2 cystatin C concentrations, 1.0 mg/L and 2.0 mg/L. The percent change in measured cystatin C values in the presence of these potentially interfering substances ranged from Ϫ1.4% to 0.6% at 1.0 mg/L and from Ϫ0.8% to 1.4% at 2.0 mg/L of cystatin C.
Discussion
We constructed the first epitope map of cystatin C involving 7 monoclonal cystatin C-antibodies using 42 2-site combinations. The ability of the monoclonal antibodies to form 2-site complexes with a single cystatin C molecule, recombinant or endogenous, was tested in an immunoassay using time-resolved fluorometry. We found numerous viable combinations, and the selection process in assay design was based on independence of epitopes, background signal, kinetics, and linearity of the dose-response curve. Three selected combinations were optimized in an all-in-one dry-reagent assay format.
Each of the 3 selected antibody pairs, HCC3-Cyst24, Cyst24-Cyst19, and Cyst28-Cyst24, facilitated reproducible and robust measurement of circulating cystatin C. The pair Cyst28-Cyst24 stood out, however, as it showed excellent linearity, fast binding, and good correlation with the PETIA assay. Furthermore, the assay demonstrated a wide linear range in measuring recombinant and native human cystatin C concentrations; the most reliable area of the standard curve (CV Ͻ10%) ranged from 0.001 to 0.2 mg/L, corresponding to plasma cystatin C concentrations of 0.1-20 mg/L. Imprecision observed throughout the measuring range was also low: total imprecision of the assay was Ͻ5.6%. By using 100-fold dilution of samples, the linear assay range covered all clinically relevant cystatin C concentrations in circulation (0.4 -14.1 mg/L (16 )), which corresponded to diluted concentrations 0.004 -0.141 mg/L. The developed assay did not show a hook effect even at 50 mg/L (with 100-fold dilution: 0.5 mg/L).
There were significant sample-specific differences between the concentrations measured with PETIA and the concentrations measured with the Cyst28-Cyst24 cystatin C assay. The differences were possibly attributable to methodological differences, such as the use of different antibodies, adoption of 2 substantially different assay formats, variability in the proneness to matrix effects, and use of different detection methodologies. The systematic difference in concentrations may be attributable to the lack of a commonly approved international standard. A potential cause for some of the observed differences in concentrations of patient samples is the use of polyclonal antibodies or monoclonal antibodies. Polyclonal antibodies used in PETIA are affinity purified and technically uniform from batch to batch. Even so, the use of polyclonal antibodies may lead to different recognition of various forms of antigen, whereas recognition by more uniformly reactive monoclonal antibodies depends on the existence and accessibility of certain epitopes.
The developed assay is sensitive and, therefore, uses extensive sample dilution, which is likely to remove possible interferences from the sample matrix. Compared with immunoturbidimetric assays, the separation step of this heterogeneous measurement also removes components that otherwise might interfere with the signal measurement.
The measured concentrations of the 13 samples labeled hemolytic and/or lipemic differed from the concentrations measured by PETIA, but these differences were within the confidence limits of the BlandAltman difference plot. Although the exact values of the interferents were not available, the results from the interference test supported the assumption that a high amount of dilution (1:300 in the final reaction mixture) and a separation step efficiently reduced interference from the sample matrix in the developed assay.
As a possible limitation to this study, a recent investigation on matrix interference suggested that PENIA might be a more reliable method than PETIA (17 ) and thus better suited to estimate reliability of a new analytical cystatin C assay. PETIA is a widely used assay and has been shown to correlate well with glomerular filtration rates obtained by gold-standard methods (18 ) , but the validity and the clinical utility of the developed assay for cystatin C remain to be confirmed by comparison with PENIA and a gold-standard method for the glomerular filtration rate. In conclusion, we have constructed an epitope map of cystatin C involving 7 monoclonal antibodies and designed a time-resolved fluorometric assay by using 2 cystatin C-specific antibodies. The assay allows rapid measurement of cystatin C and, owing to the design used, is expected to have minimal interference from sample matrices. 
